Navigation Links
Angiotech Pharmaceuticals, Inc. announces financial results for the fourth quarter ended December 31, 2009
Date:3/3/2010

addition to, and not as a substitute for, or as superior to, financial measures prepared in accordance with GAAP. A reconciliation of the Company's non-GAAP adjusted financial measures to the corresponding GAAP financial measures, and an explanation of the Company's use of these non-GAAP adjusted financial measures and of the excluded items, are included in the appendix to this press release. - Adjusted EBITDA (earnings before interest, taxes, depreciation and amortization, adjusted to exclude certain non-cash and non-recurring items) was $6.9 million. - Adjusted revenue was $63.5 million. - Adjusted costs of goods sold was $28.4 million. - Adjusted research and development expenses were $5.6 million. - Adjusted selling, general and administrative expenses were $21.2 million. - Adjusted net loss and adjusted net loss per share for the quarter were $4.7 million and $0.06, respectively.

Fourth Quarter Highlights

Proprietary Medical Products. Our Proprietary Medical Products are marketed and sold by our two direct sales groups. We believe certain of these product lines contain technological advantages that have the potential for more substantial revenue growth potential as compared to our overall product portfolio. Our most significant commercial Proprietary Medical Products are our Quill(TM) SRS wound closure product line, Skater(TM) line of drainage catheters, Option(TM) Inferior Vena Cava Filter, HemoStream(TM) chronic d
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Angiotech Pharmaceuticals Announces Conference Call and Webcast
2. Angiotech Pharmaceuticals, Inc. Announces Conference Call and Webcast
3. Angiotech Pharmaceuticals announces the commercial launch of the Option(TM) Inferior Vena Cava Filter in the United States
4. Angiotech receives approval for Quill(TM) SRS PDO, MONODERM(TM), Polypropylene and Nylon product lines for sale in Brazil
5. Angiotechs Licensee, Cook Medical, Announces CE Mark Approval and European Launch of the Zilver(R) PTX(R) Stent
6. Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
7. Angiotech Pharmaceuticals announces launch of Quill SRS product codes for laparoscopic gynecology procedures
8. Angiotech Pharmaceuticals, Inc. announces filing of shelf-registration statement
9. Angiotech Pharmaceuticals announces FDA approval of TAXUS(R) Liberte(R) Long Stent
10. Angiotech Pharmaceuticals, Inc. announces conference call and webcast
11. Angiotech Pharmaceuticals announces FDA 510(k) clearance of the Option(TM) Inferior Vena Cava Filter
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Inc. (NYSE MKT: PFNX), a clinical-stage biotechnology company ... to manufacture proteins including biosimilar therapeutics, today provided ... the second quarter ended June 30, 2014. ... public offering, we have the capital to continue ... our proprietary protein expression platform," stated Bertrand C. ...
(Date:8/29/2014)... (PRWEB) August 29, 2014 Pittcon is ... MacDonald, and colleague Koichiro Matsuda, Horiba Scientific, have organized ... September 5, 2014. JASIS , Asia’s largest analytical ... 2014, in Makuhari Messe, Japan. , The four ... for Bioanalysis from Single Molecules to Single Cells” will ...
(Date:8/29/2014)... Due to a misstatement posted by the Family ... Technology Center, LLC ( ASCTC ) was reported as an ... might benefit ALS patients. Because of ASCTC's exclusive focus ... and therapeutic applications, FRC listed ASCTC as one of several ... wish not to support research that requires the death of ...
(Date:8/28/2014)... Nevada City, CA (PRWEB) August 28, 2014 ... and sanitation products for the food processing industry, is ... conducting a side-by side comparison of the E2 soap ... Q E2 Sanitizing Foam Soap . Hand hygiene ... pathogens in the food processing environment. Six key criteria ...
Breaking Biology Technology:Pfenex Reports Second Quarter 2014 Results and Provides Business Update 2Pfenex Reports Second Quarter 2014 Results and Provides Business Update 3Pfenex Reports Second Quarter 2014 Results and Provides Business Update 4Pfenex Reports Second Quarter 2014 Results and Provides Business Update 5Pfenex Reports Second Quarter 2014 Results and Provides Business Update 6Pfenex Reports Second Quarter 2014 Results and Provides Business Update 7Pfenex Reports Second Quarter 2014 Results and Provides Business Update 8Fifth Annual U.S. Symposium at JASIS Organized by Pittcon’s Program Chairman Hub MacDonald 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 2The Adult Stem Cell Technology Center, LLC Declines ALS Ice Bucket Challenge Donors Wishing to Support Ethical Research for New Stem Cell Therapies 3Best Sanitizers, Inc. Asks Food Industry Professionals: With Fall Harvest On the Way, Is Your E2 Hand Soap Up to the Task? 2
... hurricane that smashed into New York in 1938 to the ... and 20th centuries are rich with examples of extreme weather. ... reanalysis of all global weather events from 1871 to the ... stream level. The 20th Century Reanalysis Project, outlined ...
... Incorporated (Nasdaq: SPEX ), an innovator ... atherosclerosis; and providers of technical and regulatory consulting services ... the closing of previously reported agreements to sell $2.77 ... to purchase shares of its common stock in a ...
... Sensus Healthcare is pleased to announce its ... products to be exclusively offered by our physician partners. ... cancer are on the rise and are dramatically escalating ... aim at skin cancer (SM) in innovative ways. On ...
Cached Biology Technology:The 20th Century Reanalysis Project: A time machine for climate scientists 2The 20th Century Reanalysis Project: A time machine for climate scientists 3Spherix Announces Closing of Registered Direct Offering of $2.77 Million in Common Stock and Warrants 2Spherix Announces Closing of Registered Direct Offering of $2.77 Million in Common Stock and Warrants 3Sensus Healthcare Announces New Professional Skin Care Line - Sensus Skin Solutions™ 2
(Date:8/29/2014)... known about what genetic changes transform wild animals into ... whom is a University of Montana assistant professor, has ... development of the brain and the nervous system were ... Aug. 28 in Science and gives answers ... http://www.sciencemag.org/ ., The domestication of animals and plants, a ...
(Date:8/29/2014)... is available in German . ... between organisms is considered the oldest form of communication. ... conspecifics, for example, the sexual attraction between males and ... and to coordinate reproductive behavior in males and females. ... of the Algarve in Faro, Portugal, and at the ...
(Date:8/28/2014)... now available from the Lady Bird Johnson Wildflower Center ... harmful non-native plant, insect and other invasive species statewide. ... about $137 billion in economic and other damage annually ... plants and more. , "By having streamlined tools like ... occur, we,re more likely to catch these threats early ...
Breaking Biology News(10 mins):New research reveals how wild rabbits were genetically transformed into tame rabbits 2New research reveals how wild rabbits were genetically transformed into tame rabbits 3Ready for mating at the right time 2Ready for mating at the right time 3Mobile app makes ID of harmful plants, insects in Texas a snap 2
... San Diego NanoEngineers won a grant from the National ... manufacture biodegradable frames around which heart tissues functional ... growing tissues that mimic nature,s fine-grained details, including vasculature, ... cardiac tissues for people who have suffered a heart ...
... plants, including crops, release volatiles in response to insect ... can be an aromatic call for help to attract ... Michigan State University, and Georg-August-University Gttingen have discovered how ... reported this week in the online early edition of ...
... major obstacle in curing ovarian cancer but new research from ... cancer cells in a new way that can break the ... researchers found the drug (FTY720) had a potent effect in ... the most commonly used chemotherapeutic drug currently available for the ...
Cached Biology News:Nanoengineers aim to grow tissues with functional blood vessels 2Nanoengineers aim to grow tissues with functional blood vessels 3Biochemistry of how plants resist insect attack determined 2New treatment to overpower drug resistance in ovarian cancer 2
Viral CCI Biotinylated Affinity Purified PAb...
Human RXR beta/NR2B2 MAb (Clone H7341) Keywords: RXRbeta, RXRbeta, Retinoid X Receptor beta...
Human SOST Affinity Purified Polyclonal Ab...
BOND ELUT MATRIX-C18, 25 mg ...
Biology Products: